ITA8092
ITA8092
ITA8092
from
$526.00
Price in reward points: 526
- Catalog: ITA8092
- Gene/Protein: CD82
- Product Description: Immunotag™ CD82 Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein CD82 Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,ELISA Recommended Dilution WB 1:1000-3000,IHC 1:50-1:200 Concentration 1 mg/ml Reactive Species Human Host Species Rabbit Immunogen A synthesized peptide derived from human CD82 Specificity CD82 Antibody detects endogenous levels of total CD82 Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name CD82 Accession No. P27701 Alternate Names 4F9; Antigen detected by monoclonal and antibody IA4; C33; C33 antigen; CD 82; CD82; CD82 antigen; CD82 molecule; CD82_HUMAN; GR 15; GR15; IA 4; IA4; Inducible membrane protein; Inducible membrane protein R2; KAI 1; KAI1; Kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)); Kangai 1; Kangai1; Leukocyte surface antigen R2; Metastasis suppressor Kangai 1; Metastasis suppressor Kangai-1; Metastasis suppressor Kangai1; Prostate cancer antimetastasis gene KAI1; R2; R2 leukocyte antigen; SAR 2; SAR2; ST 6; ST6; Suppression of tumorigenicity 6; Suppression of tumorigenicity 6 prostate; Suppressor of tumorigenicity 6; Suppressor of tumorigenicity 6 protein; Tetraspanin 27; Tetraspanin-27; Tetraspanin27; Tspan 27; Tspan-27; Tspan27; Description Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 30 kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | CD82 |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,ELISA |
| Recommended Dilution | WB 1:1000-3000,IHC 1:50-1:200 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human CD82 |
| Specificity | CD82 Antibody detects endogenous levels of total CD82 |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | CD82 |
| Accession No. | P27701 |
| Alternate Names | 4F9; Antigen detected by monoclonal and antibody IA4; C33; C33 antigen; CD 82; CD82; CD82 antigen; CD82 molecule; CD82_HUMAN; GR 15; GR15; IA 4; IA4; Inducible membrane protein; Inducible membrane protein R2; KAI 1; KAI1; Kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)); Kangai 1; Kangai1; Leukocyte surface antigen R2; Metastasis suppressor Kangai 1; Metastasis suppressor Kangai-1; Metastasis suppressor Kangai1; Prostate cancer antimetastasis gene KAI1; R2; R2 leukocyte antigen; SAR 2; SAR2; ST 6; ST6; Suppression of tumorigenicity 6; Suppression of tumorigenicity 6 prostate; Suppressor of tumorigenicity 6; Suppressor of tumorigenicity 6 protein; Tetraspanin 27; Tetraspanin-27; Tetraspanin27; Tspan 27; Tspan-27; Tspan27; |
| Description | Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 30 kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |